•Airtel Africa has appointed additional investment bankers to prepare for the initial public offering of its mobile money unit on the London Stock Exchange.
•The flotation is expected to raise approximately $1.5bn, potentially providing a boost to the UK's public markets.
•The U.S. Food and Drug Administration (FDA) has accepted Axsome Therapeutics' New Drug Application (NDA) for AXS-12 for the treatment of cataplexy in narcolepsy.
•The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.
